LUGANO, Switzerland,
July 1, 2016 /PRNewswire/ --
Helsinn, the Swiss pharmaceutical Group focused on building
quality cancer care, today announces that the Company has signed an
agreement, with Vifor Pharma ("Vifor") for the promotion and
distribution of Aloxi®, an anti-nausea therapeutic
medicine used to help prevent symptoms of chemotherapy-induced
nausea and vomiting (CINV), in Spain. The agreement will commence on
1 July 2016.
This agreement builds on the existing agreement with Vifor for
the promotion and distribution of Akynzeo®, the oral
fixed combination of netupitant and palonosetron, developed for the
prevention of CINV, in Spain,
France, Switzerland, Portugal and the Benelux region. Previously,
Aloxi® was distributed by Italfarmaco in Spain, however, due to the portfolio synergies
with Vifor in other European countries, the agreement will now
terminate on 1 July 2016. Under the
terms of the new agreement with Vifor, Helsinn retains rights to
all clinical development, international regulatory activities and
the manufacturing and supply of Aloxi®. Vifor will have
exclusive rights to promotion and sales of Aloxi® in
Spain.
Riccardo Braglia,
Helsinn Group Vice Chairman and CEO, commented:
"We are pleased to be able to strengthen our
existing relationship with Vifor, a valued and trusted
partner, through this agreement in Spain. This agreement
complements Helsinn's existing agreement with Vifor
on Akynzeo® and we look forward to
working closely on this new, expanding partnership."
About the Helsinn Group
Helsinn is a privately owned cancer supportive care
pharmaceutical group with an extensive portfolio of marketed
products and a broad development pipeline. Since 1976, Helsinn has
been improving the everyday lives of patients, guided by core
family values of respect, integrity and quality, through a unique
integrated licensing business model working with long standing
partners in pharmaceuticals, medical devices and nutritional
supplement products. Helsinn is headquartered in Lugano,
Switzerland, with operating
subsidiaries in Ireland and the
US, a representative office in China, as well as a product presence in about
90 countries globally.
In 2016, our 40th anniversary year, you can meet
representatives from Helsinn at:
- ChemOutsourcing Conference (Parsippany, New Jersey, 19-21 September)
- CPhI Worldwide (Barcelona,
Spain, 4-6 October)
- ESMO Congress (Copenhagen,
Denmark, 7-11 October)
- BioEurope (Köln, Germany, 4-6
November)
For more information, please visit http://www.helsinn.com.
About Vifor Pharma
Vifor Pharma, a company of the Galenica Group, is a world leader
in the discovery, development, manufacturing and marketing of
pharmaceutical products for the treatment of iron deficiency. The
company also offers a diversified portfolio of prescription
medicines as well as over-the-counter (OTC) products. Vifor Pharma,
headquartered in Zurich,
Switzerland, has an increasingly global presence and a broad
network of affiliates and partners around the world.
Galenica is a diversified Group active throughout the
healthcare market which, among other activities, develops,
manufactures and markets pharmaceutical products, runs pharmacies,
provides logistical and database services and sets up networks.
With its two Business units Vifor Pharma and Galenica Santé, the
Galenica Group enjoys a leading position in all its core business
activities. A large part of the Group's income is generated by
international operations. Galenica is listed on the Swiss Stock
Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
For more information about Vifor Pharma and its parent company
Galenica, please visit
http://www.viforpharma.com and http://www.galenica.com.
For more information, please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
Tel: +41-91-985-21-21
info-hhc@helsinn.com